IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	David P. BINGAMAN)	Examiner: Fay, Zohreh A
Serial No:	10/545,055 (Conf. #3542))	Group Art Unit: 1618
Filed:	August 10, 2005)	Docket No.: 2462 US F

FOR: USE OF STEROIDS TO TREAT OCULAR DISORDERS

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. 1.56, 1.97, AND 1.98

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants submit the patents, articles, and other information referenced in the specification as filed. The references are listed on the attached PTO Form 1449. Applicants are submitting copies of the foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2), no copies of the U.S. patents/patent application publications are provided.

It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 501051.

Applicants request that the listed patents, articles, and other information be considered during prosecution of this application and that they appear among the "References Cited" on any patent issuing herefrom.

Respectfully submitted,

Registration No. 40,256

817-551-4231

Address for Correspondence: Alcon Research, Ltd. Attn: Teresa J. Schultz 6201 S. Freeway, Mail Code Q-148 Fort Worth, TX 76134-2099 Phone: 817-551-4321

Attorney Docket No.: 2462 US F